SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.85-4.5%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Crossy who wrote (5933)3/18/2002 9:52:36 PM
From: John Metcalf  Read Replies (1) of 52153
 
Crossy, thanks for the information. As I read it, JT only sold the over-the-counter part of its drug operations, and did so in order to focus on drug development: jtnet.ad.jp

You asked if JT's effort was substantial. They partially funded development of Agouron's Viracept for HIV. They owned 50% of Xenotech, developer of Xenomouse fully human antibody technology (which now belongs to ABGX). They sold a crop technology to Dow Chem.

I don't know how much of the research was done by JT, but someone over there has made some good decisions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News